Post

The Drug That Never Stops Working

Pharmaceutical wastewater has become one of the most dangerous and least discussed pollutants on the planet. ARBOK-PHARMIX technology offers a solution that global industry has been waiting for decades. When a patient takes medication — whether…

Pharmaceutical wastewater has become one of the most dangerous and least discussed pollutants on the planet. ARBOK-PHARMIX technology offers a solution that global industry has been waiting for decades.

When a patient takes medication — whether an antibiotic, vitamins, aspirin, or a hormonal drug — the body absorbs only a small fraction of the active substance. The rest is excreted, flushed down the toilet, enters the sewage system, passes through municipal treatment plants — and ends up in the river, crossing over from the side of good to the side of harm.

Wastewater treatment plants in their current form were developed about 100 years ago. They were never designed to process chemical waste and were built exclusively to handle organic household and sewage waste — not to break down molecules of synthetic hormones, fluoroquinolone antibiotics, or other chemical compounds. These substances are poorly and incompletely removed by classic treatment systems, and after treatment they end up in rivers. That means cities located downstream draw drinking water from those same rivers and lakes. River water is cleaned with the same reverse osmosis used for various organic pollutants. But RO cannot remove dissolved chemical compounds present in trace concentrations. The membrane lattices simply cannot hold back such substances, and they pass through. Today, even officially “purified” drinking water contains traces of antibiotics, hormones, and pesticides from farm fields — and all of them end up in our kettles or pots, and on our skin when we wash or shower.

Of the roughly 31,000 tons [of what???] consumed annually by humanity, only forty [what is this???] of the most common antibiotics account for around 9,500 tons — a third — entering the world’s river systems [REWRITE THIS SENTENCE! THIS IS TERRIBLE!]. Across the environments of 71 countries, 631 pharmaceutical compounds have been recorded, while around 4,000 active substances are used in medical practice in total — most of which have never even been tested for presence in water bodies.

Synthetic hormones alter the reproductive system of aquatic fauna — including the very fish we eat. At a concentration of just 1 nanogram per liter — one billionth of a gram — [FINISH THE THOUGHT!] fish suffer damage that is irreparable and represents a serious deviation from the norm, preventing their reproduction. In some British rivers, the share of intersex individuals exceeded 80%. And that’s just for fish… The root of the problem isn’t the unfortunate mutated fish. It also affects other aquatic fauna, birds, and so on. The root is that as the population grows, the amount of pollution in the water increases, posing a real threat to both wildlife and humanity itself. This waste — silent killers, like PFAS.

80 to 90% of the world’s antibiotics are produced at factories in India and China, where environmental requirements have historically always been weak or nonexistent. That’s precisely why the British moved all their pharmaceutical production to India. Near pharmaceutical plants in India, high concentrations of ciprofloxacin are recorded — a broad-spectrum antibiotic from the fluoroquinolone group, one of the key drugs for treating pneumonia, severe urinary tract infections, and sepsis. It should only be taken with a doctor’s prescription and in carefully measured doses. It’s a powerful drug that is dangerous to the human body. Its particular danger is that a bacterium that develops resistance to it simultaneously loses sensitivity to most other first-line antibiotics and becomes practically invulnerable in clinical settings — in factory effluent at levels of 28–31 mg/L. Then you take antibiotics, and they don’t work… From just one industrial cluster, more than 100 kilograms of this single antibiotic flow into nearby rivers every day. Just this one! And there are others! This exact environment is an ideal incubator for resistant strains, which then show up in intensive care units in London, Berlin, and New York. According to WHO data, antibiotic-resistant infections already claim more than a million lives a year. Chinese researchers have found that treatment plants near pharmaceutical facilities release on average 4–5 times more antibiotic-resistant bacteria than they take in. The plant doesn’t eliminate the threat — it amplifies it.

To understand why traditional technologies can’t cope, it’s enough to recall what they were built for. The biological stage — aerobic bacteria that break down organic matter — works by processing household organic waste. For these bacteria, pharmaceutical molecules are an enemy and a potent poison. These APIs — active pharmaceutical ingredients — simply kill off the very bacteria that decompose our waste. We first kill the aerobic bacteria, and then expect them to break down our toilet and other organic waste. As we know, dead things don’t work. Chlorination, used today, turns APIs into compounds that are even more toxic. Reverse osmosis membranes clog and break down on contact with solvents and surfactants that are inevitably present in pharmaceutical effluent. The expensive polyamide materials the membranes are made from react chemically with the incoming pollutants — they were never designed for this and degrade quickly. A single industrial RO membrane costs around $1 mln. And there isn’t just one or two of them. Another commonly used filtration method is activated carbon. It’s a consumable — and that’s already a problem. Such carbon becomes saturated with chemicals within hours at industrial volumes and requires frequent replacement. As a result, the industry spends enormous amounts of money — without solving the problem, merely plugging holes. If you think that at municipal utilities, sewage water or household effluent is well treated before being sent into rivers — you’re lucky. It means you don’t know anything, but you sleep well.

Specific numbers matter here more than any general statements. An average bulk-drug manufacturing plant somewhere in India or China — where 80% of the world’s raw pharmaceutical material is produced — with a wastewater volume of 500 m³/day, contains roughly 100–300 tons of API (active pharmaceutical ingredient — the chemical active substance directly producing the therapeutic effect) per year. Such a plant spends $500K to $3 mln annually on treatment facilities, depending on the technology used and the degree of actual regulatory compliance. As we understand, it treats poorly, but is obligated to do so, while preferring to stay silent about actual discharge parameters — otherwise it would be shut down.

The resulting liquid and especially hazardous waste is typically treated using the notorious Zero Liquid Discharge (ZLD) method. Why “notorious”? To “get rid of” chemically contaminated waste, the water is fully evaporated down to dry residue — this takes up less space for disposal at chemical landfills. Using a mechanical evaporator (MEE) is a highly inefficient undertaking, and this follows directly from math and physics: evaporation requires 150–250 kWh for every ton of water. Do the math yourself — at a European price of around €0.40 per kWh, that’s €60–100 in pure energy costs for every cubic meter of evaporated water, not counting equipment depreciation, chemical pretreatment, maintenance, and concentrate disposal. And this process doesn’t solve environmental problems at all — it merely shifts them from the liquid phase to the solid phase. Capital costs — plus space, infrastructure, and hazardous vapor emissions into the atmosphere — run $1.5–3.5 mln, and then eat up another $250–600 for every cubic meter of dried concentrate. The full real cost of ZLD at most operating pharmaceutical facilities is $30–50 per cubic meter of treated water. That means the same plant, at 500 m³/day, pays $5.5–9 mln a year for “treatment” — not counting that it then has to buy the water back again. The right question here is: who could have come up with ZLD, who could buy into it — and why pay up to $9 mln without actually solving the problem, when you could pay 30–60 times less and solve it once and for all?

A large European or American pharmaceutical plant — sites like Roche, Novartis, Pfizer, with effluent volumes of 1,000 to 5,000 m³/day — pays even more: $20–40 per cubic meter of treated water, accounting for biological, chemical, and membrane cascades. For a plant at 2,000 m³/day, that’s $15–30 mln a year on water treatment alone. In January 2025, the EU’s new Urban Wastewater Treatment Directive came into force, under which pharmaceutical manufacturers bear extended responsibility for removing micropollutants — including their own APIs — from municipal treatment plants. The European Commission estimated the additional burden on the industry at €1.2 bln a year from this provision alone. The combined direct and indirect costs of wastewater management for the global pharmaceutical industry are now estimated at $5–7 bln a year. The money keeps flowing out — the problem remains.

It’s in this context that ARBOK-PHARMIX appears. The process runs under deep vacuum and at ambient temperature — from 6 to 40°C. Under vacuum, the wastewater in the unit boils at ordinary room temperature and evaporates: lighter molecules pass into vapor, while heavier and less volatile ones — including APIs, hormones, antibiotics — concentrate in the liquid phase and settle at the bottom of the unit as a layered concentrate. This separation happens without catalysts, without membranes, without chemical reagents, and without any consumables. Only electricity — 0.72 kWh/m³ net. Not 150–250 kWh per ton, but 0.72 kWh per ton — 70 to 125 times less! That’s it. The extracted concentrate of pharmaceutical compounds is then separated on-site into its components and discharged from the unit in dry form — if it’s salts or metals — or as acids of various purity and concentration. All these materials have strong market demand and commercial value — what used to be flushed into the sewer becomes a source of revenue. The purified water — more than 99.9% of the original volume — is produced without generating any other type of waste stream. The water is completely clean and goes straight back into the production cycle without any additional processing. In effect, the pharmaceutical plant removes water purchasing from its cost line entirely. The Arbok-PHARMIX module captures all heavy and dissolved particles in the water; the exiting vapor is purified down to particle sizes below 30 nanometers — a range unattainable by RO, ZLD, or activated carbon. All captured compounds are separated and form a class of useful by-products that can be reused for production purposes.

What does this mean in money terms for that same Indian plant handling 500 m³/day? Electricity cost at $0.08/kWh — about $10,200 a year. Cost of purchasing water — about $150K a year (now fully returned to the cycle). Purchase of chemical reagents — about $600K a year (now no longer needed). Additionally — revenue from selling the acids, salts, and metals recovered at the unit’s output: roughly $150–300K a year depending on effluent composition. Even accounting for full OPEX, including depreciation of the unit — around $120–200K a year. That means the cost side shrinks to $120–200K versus $5.5–9 mln today — a 30–45x reduction. This approach makes it possible to cut costs by 96–98%, enabling a more aggressive market strategy — offering discounts or lowering the selling price. Even with an 8–12% discount, this can drive a 20–35% increase in sales volume without sacrificing margin.

For a large European plant handling 2,000 m³/day: electricity at €0.30/kWh — about €153K a year, full OPEX — $800–1,200K. Versus €15–30 mln. While part of the savings improves the plant’s own economics, part can go toward price competitiveness — the payback period comes to roughly 5–7 years, considerably shorter than the payback of conventional, technically complex, and yet largely ineffective treatment facilities.

But it’s not just the savings figure that matters — it’s the logic behind it. All existing technologies — biological, membrane, carbon, evaporative — come from the distant past and are completely out of step with the realities of the 21st century. They’re built on a single idea: dilute the dangerous compounds in water, then try to extract them at any cost — or at least some of them. This is a fundamentally losing strategy, and it’s precisely what absorbs up to $8 bln a year for zero environmental result. ARBOK-PHARMIX works on the opposite principle. No contaminants — organic matter, antibiotics, hormones, synthetic substances — ever end up in the purified water at all. They all stay inside the unit, get separated into their components, and come out as dry salts, metals, or acids. Not as an unavoidable waste product — but as a useful one. This isn’t water treatment. This is Zero Waste Discharge in its fullest sense. This is pollution prevention at the source — the only approach in the world where the problem isn’t merely “reduced” to regulatory levels at the cost of tons of chemicals, membranes, and equipment, turning one type of waste into several others, each requiring further disposal. Here, physics isn’t being forced — it’s working for people.

Growing regulatory pressure only makes this argument more compelling. Every new regulation — Indian, European, American — isn’t a threat to companies that have adopted PHARMIX; it’s an added bill for those still paying for technologies that don’t solve the problem. The math has already changed. What remains is for the industry’s decision-makers to notice.

Medicine heals. At the same time, it poisons the rivers where fish live, where birds are born and raised, fish that people eat, people who then need medicine. This closed loop existed only because a technology to break it didn’t exist. Now it does — this isn’t a miracle from a lab test tube, this is TRL-9, meaning maximum technological readiness. ARBOK-PHARMIX works without heating, without chemicals, without consumables, and without liquid waste — it keeps inside itself what should never reach the river, and returns to production what was spent. The question isn’t whether ARBOK-PHARMIX will be adopted. The only question is how much more will be wasted, and how many more deaths from antibiotic-resistant infections will need to be recorded, before drug manufacturers finally reckon with the true cost of their own inaction.


Also published on: LinkedIn — Michael Vischmidt · Facebook — ARBOK Institute